Instalab
logoInstalab

Potassium

Blood Test
One of the most important checks for heart rhythm safety, especially if you take blood pressure medications or have any kidney concerns.
4.8 (4,029 reviews)
Tested by Quest, Access Medical or Boston Heart
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a Potassium test?

This test is most useful if any of these apply to you.

Taking Blood Pressure Medications
If you take an ACE inhibitor, ARB, spironolactone, or a diuretic, your potassium can drift in either direction and needs regular checking.
Living with Kidney Concerns
Reduced kidney filtration is the most common cause of high potassium, and even mild decline can shift your levels toward a danger zone.
Managing Heart Failure
Both low and high potassium raise mortality in heart failure, and your target window is narrower than the standard normal range.
Healthy but Want to Stay Ahead
A baseline reading tells you where you sit on the U-shaped risk curve and gives you a reference point before any future medication or kidney changes.

About Potassium

Potassium is the mineral most tightly linked to whether your heart beats in a normal rhythm. When your level drifts even modestly outside a narrow window, the risk of dangerous arrhythmias, hospitalization, and death climbs measurably. That is why potassium is one of the few electrolytes where both too little and too much are genuinely dangerous, not just uncomfortable.

The number you see on a lab report reflects a small extracellular pool that your body defends aggressively through kidney excretion and moment-to-moment shifts between blood and cells. Understanding this pool matters most if you take blood pressure medications, have any kidney concerns, or want an early warning that your electrolyte balance is under strain.

The U-Shaped Risk Curve

Unlike many biomarkers where higher is always worse or lower is always better, potassium follows a U-shaped pattern. In a pooled analysis of about 1.2 million people followed for nearly seven years, the lowest mortality clustered between 4.0 and 4.5 mmol/L, with the specific nadir around 4.2 mmol/L. Compared with people at that sweet spot, all-cause mortality was roughly 22% higher at 5.5 mmol/L and about 50% higher at 3.0 mmol/L.

This is not a paradox once you understand what potassium does. It sets the electrical resting state of every heart muscle cell. Push it too high and the heart's electrical repolarization shortens, which can trigger arrhythmia and even cardiac arrest. Push it too low and the heart's action potential lengthens, which also destabilizes rhythm. So potassium is not a "higher good, lower bad" number. It is a narrow-target number, and both directions of drift carry cardiac cost.

Heart Rhythm and Arrhythmia

The clearest reason to know your potassium is arrhythmia risk. In older adults, low serum potassium was associated with about 60% higher risk of supraventricular arrhythmias (irregular heartbeats originating above the ventricles). After a heart attack, high potassium was associated with roughly 2.3 times the risk of ventricular arrhythmias, the dangerous rhythms that cause sudden cardiac death.

In hospitalized general-ward patients, mortality began rising once potassium moved into the 4.6 to 5.0 mmol/L range, and it more than doubled above 5.5 mmol/L. In critical care with sepsis, an inflection point emerged at 4.4 mmol/L, above which 28-day death risk was roughly three times higher. Even variability inside the normal range matters: hospitalized patients whose potassium swung the most were about three times more likely to die during that admission than those whose values stayed steady.

Kidney Function

Your kidneys handle about 90% of daily potassium removal, so any decline in kidney function eventually shows up as a rise in potassium. In older adults with advanced CKD (chronic kidney disease), the risk of death or needing dialysis was lowest when potassium sat in roughly the 4.0 to 5.0 mmol/L range, and climbed at both lower and higher values. In non-dialysis CKD, mortality rates were roughly 3 times higher at potassium below 3.5 mEq/L and 3.3 times higher at 6.0 mEq/L or above compared with normal ranges.

This matters even if you have never been told you have CKD. Kidney function declines gradually with age, and potassium is often one of the first electrolytes to shift when filtration slips. If you take medications that further limit potassium excretion, that hidden kidney reserve gets exposed.

Heart Failure

In heart failure, both low and high potassium track worse outcomes, and the target window is even tighter. In a UK cohort of over 21,000 heart failure patients, mortality was roughly 2 times higher below 3.5 mmol/L and about 3 times higher at 6.0 mmol/L or above, compared with the 4.5 to 5.0 mmol/L reference range. A more recent individual patient meta-analysis of over 46,000 heart failure patients pointed to a slightly wider optimal window of about 4.2 to 5.0 mmol/L.

The wrinkle is that many core heart failure medications, including ACE inhibitors (a class of blood pressure drugs), ARBs (angiotensin receptor blockers, another blood pressure class), and mineralocorticoid receptor antagonists (aldosterone-blocking drugs like spironolactone), raise potassium as a side effect. Fear of hyperkalemia often leads to under-dosing of these life-extending medications, which itself worsens outcomes.

Blood Pressure and Cardiovascular Prevention

Higher dietary potassium intake lowers blood pressure in people with hypertension, with pooled reductions around 3.5 mmHg systolic and 2.0 mmHg diastolic. In hypertensive adults specifically, dose-response analyses suggest that a 50 mmol/day increase in urinary potassium (a marker of intake) is linked to a roughly 5 mmHg drop in systolic pressure. Higher intake was also linked to about 24% lower stroke risk in observational analyses.

This is where the two sides of potassium diverge. Dietary intake tends to help blood pressure and stroke risk in people with normal kidney handling. But in CKD, the same intake can push serum potassium into a danger zone. Two people can take the same action and get opposite results, which is one reason knowing your baseline number matters before making changes.

Tracking Your Trend

Potassium is unusually variable within the same person, even under standardized conditions. In one study of 1,170 outpatients tested repeatedly, about 12% of paired differences exceeded 0.5 mmol/L, and 44% of people whose average value was high had at least one normal reading, while 30% of people whose average was normal had at least one high reading. A single value can miss real problems or invent false ones.

For that reason, a trend across at least two or three tests carries more weight than any one reading. Get a baseline. If you are starting or adjusting a blood pressure medication, diuretic, or potassium supplement, retest in about 1 to 2 weeks, then again at 3 months. Once stable, retest at least annually, or every 3 to 6 months if you have CKD, heart failure, or are taking multiple potassium-affecting drugs. Watching whether your value drifts toward the edges of the safe zone is more useful than knowing where it sits today.

When Results Can Be Misleading

Potassium is notoriously easy to distort during sample handling. The problem is common enough that in one emergency department review, about 35% of initial elevated potassium results normalized on same-day repeat testing, and 69% of those false elevations showed hemolysis (red blood cells that ruptured in the tube, spilling their potassium). In one primary care cohort, 86% of initially elevated results were normal on repeat within 8 days.

  • Hemolysis and collection technique: rough draws, small needles, fist clenching, or a tight tourniquet can rupture red blood cells and spuriously raise potassium. The size of the effect varies widely with the degree of hemolysis, from clinically negligible to large enough to mimic true hyperkalemia. Hemolysis can also mask a true low value.
  • Sample type: serum values run roughly 0.1 to 0.4 mmol/L higher than plasma because potassium leaks from platelets as blood clots. Very high platelet counts above 500,000 can amplify this gap.
  • Delayed processing: samples that sit too long before analysis show creeping potassium rises. Longer transport times were linked to more false hyperkalemia results.
  • Transient shifts: intense exercise just before a draw, a heavy meal, insulin dosing, or acute stress can move potassium briefly without indicating real disease. These normalize within hours.

If you get an unexpected result, especially one that doesn't fit your symptoms or ECG, the right first move is usually to repeat the test with clean collection technique before making treatment decisions.

What to Do With an Out-of-Range Result

An abnormal potassium is a starting point, not a diagnosis. The next question is why. That answer usually comes from combining potassium with a small set of companion tests and a careful medication review.

  • Confirm it is real: repeat the test with attention to hemolysis, especially if you had a difficult draw or the result surprises you.
  • Check kidney context: pair with creatinine, cystatin C, and eGFR (a calculated measure of how well your kidneys filter blood). Reduced kidney function is the most common reason for a truly high value.
  • Review medications: ACE inhibitors, ARBs, MRAs, potassium-sparing diuretics, NSAIDs (non-steroidal anti-inflammatory drugs like ibuprofen), and trimethoprim (an antibiotic) can raise potassium. Loop and thiazide diuretics, laxatives, and steroids can lower it.
  • Consider an ECG: for meaningfully high or low values, an electrocardiogram checks whether the abnormal potassium is already affecting your heart's electrical activity. But a normal ECG does not rule out a dangerous value, so blood testing remains the reference.
  • Look for secondary causes: unexplained low potassium plus high blood pressure should trigger evaluation for primary aldosteronism (an adrenal hormone disorder), one of the most underdiagnosed causes of stubborn hypertension.

What Moves This Biomarker

Evidence-backed interventions that affect your Potassium level

Increase
Take a potassium-sparing diuretic or MRA (like spironolactone)
Mineralocorticoid receptor antagonists and other potassium-sparing diuretics reliably raise serum potassium by blocking aldosterone-driven excretion, and hyperkalemia is a well-known reason for stopping these drugs. The effect is amplified when combined with ACE inhibitors, ARBs, NSAIDs, or trimethoprim.
MedicationStrong Evidence
Decrease
Take a loop or thiazide diuretic
Thiazide and loop diuretics are the most common medication cause of low potassium, working through increased renal loss. In a randomized trial, chlorthalidone caused potassium at or below 3.5 mEq/L in about 23% of participants during the first year, compared with 3.1% on placebo. Low potassium in this setting has been linked to a higher risk of new-onset diabetes.
MedicationStrong Evidence
Decrease
Receive insulin plus glucose for acute hyperkalemia
In acute hyperkalemia treatment, insulin combined with glucose shifts potassium into cells and lowers serum values by about 0.7 to 1.2 mmol/L on average. This is an emergency intervention used in hospital settings, not a chronic therapy.
MedicationStrong Evidence
Decrease
Receive nebulized salbutamol for acute hyperkalemia
Nebulized salbutamol at 10 mg lowers serum potassium by 0.6 to 1.6 mEq/L with peak effect at 1 to 4 hours after administration. Used in emergency management of severe hyperkalemia, often alongside insulin plus glucose.
MedicationStrong Evidence
Increase
Take an ACE inhibitor or ARB
ACE inhibitors and ARBs raise potassium by reducing the kidney's ability to excrete it, and were the antihypertensive drug classes most strongly associated with hyperkalemia in a large healthcare-system study. This side effect is more pronounced with CKD, older age, diabetes, or when combined with other potassium-raising drugs, and can require dose reduction or additional monitoring.
MedicationModerate Evidence
Increase
Take trimethoprim (antibiotic, often as Bactrim)
Trimethoprim blocks a kidney sodium channel similar to how the potassium-sparing diuretic amiloride does, which reduces potassium excretion. Risk rises with higher treatment doses used for pneumocystis pneumonia, but even standard doses can cause hyperkalemia, particularly with other potassium-raising drugs or reduced kidney function.
MedicationModerate Evidence
Up & Down
Increase dietary potassium intake
In people with normal kidneys, higher potassium intake modestly raises serum potassium and meaningfully lowers blood pressure, with pooled reductions of about 3.5 mmHg systolic and 2.0 mmHg diastolic. In hypertensive adults, dose-response analyses suggest a 50 mmol/day increase in intake is associated with a roughly 5 mmHg systolic drop, and higher intake tracks with about 24% lower stroke risk. However, in CKD stage 3 to 4, 40 mmol/day of potassium chloride for two weeks raised plasma potassium from 4.3 to 4.7 mmol/L, and 11% of participants developed hyperkalemia.
DietModerate Evidence
Increase
Take NSAIDs (like ibuprofen or naproxen) regularly
NSAIDs blunt kidney prostaglandin production, which reduces potassium excretion and can push levels up. The risk is small in healthy people but meaningful in those with reduced kidney function or already taking ACE inhibitors, ARBs, or diuretics. Chronic use combined with these drugs is a common trigger for outpatient hyperkalemia.
MedicationModest Evidence

Frequently Asked Questions

References

22 studies
  1. Kovesdy CP, Matsushita K, Sang Y, Brunskill NJ, Carrero JJ, Chodick G, Hasegawa T, Heerspink HL, Hirayama a, Landman GW, Levin a, Nitsch D, Wheeler DC, Coresh J, Hallan SI, Shalev V, Grams MEEuropean Heart Journal2018
  2. Fan Y, Wu M, Li X, Zhao J, Shi J, Ding L, Jiang H, Li Z, Zhang W, Ma T, Wang D, Ma LNutrition Journal2024
  3. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FPThe BMJ2013
  4. Palaka E, Grandy S, Darlington O, Mcewan P, Van Doornewaard aInternational Journal of Clinical Practice2020